(3S)-1-[(4-Methylphenyl)Sulfonyl]-Diphenyl-3-Pyrrolidineacetonitrile

Why Tosyl Cleavage Temperature Must Stay Below 78°C in Darifenacin Hydrobromide Synthesis

Conversion of (3S)-1-[(4-Methylphenyl)Sulfonyl]-Diphenyl-3-Pyrrolidineacetonitrile into the selective M₃ muscarinic antagonist darifenacin hydrobromide proceeds through a sequence of N-detosylation, nitrile reduction, and N-alkylation with 2-(2-bromoethyl)-2,3-dihydrobenzofuran. Industrial campaigns scaling to 120 kg input routinely execute the detosylation in a 1:4 (v/v) mixture of 48% aqueous HBr and glacial acetic acid, with the internal temperature programmed from 20°C to 72 ± 3°C over 45 min and held for 4.5–5.5 h. Exceeding 78°C triggers runaway nitrile solvolysis to the primary amide and subsequent hydrolysis to the carboxylic acid, reducing HPLC purity below the 99.0% threshold required for subsequent step. Glass-lined reactors equipped with Hastelloy C-22 overhead condensers are preferred because the mineral acid vapors attack 316L stainless steel at the reflux boundary, generating trace metal contamination that fouls the Raney nickel catalyst in the next hydrogenation stage. End-of-reaction monitoring by reversed-phase UPLC (C18, 1.7 µm, gradient MeCN/0.1% TFA) quantifies residual sulfonamide <0.3 area% and amide hydrolysis impurity <0.15 area%. After quenching into ice-cold deionized water and extraction with dichloromethane, the crude free base is crystallized from n-heptane/ethyl acetate (4:1) to furnish (S)-α,α-diphenyl-3-pyrrolidineacetonitrile in 82–88% isolated yield with an enantiomeric excess of ≥99.5% by chiral HPLC (Chiralpak IA, hexane/EtOH/DEA 90:10:0.1). This intermediate is then charged to a hydrogenation autoclave with Raney 2800 nickel slurry at 8 ± 0.5 wt% relative to substrate, methanolic ammonia (7.0 M) as the amine-protecting solvent, and hydrogen at 55–60 psi at 38–42°C for 6–8 h. Under these conditions, over-reduction of the diphenylmethane moiety or ring saturation remains below the limit of detection, while primary amine content by titration exceeds 97.5%. The final alkylation with the benzofuranethyl bromide employs a 1:1.03 molar ratio of amine to electrophile in refluxing acetonitrile with anhydrous K₂CO₃ (2.2 equiv) and a catalytic quantity of KI (0.05 equiv) to suppress dialkylated quaternary salt formation, consistently producing darifenacin base with a purity profile suitable for hydrobromide salt formation and subsequent formulation into extended-release tablets of 7.5 mg and 15 mg dose strengths (Enablex^® and generic equivalents). Regulatory compliance for the titled intermediate demands adherence to ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients, control of residual solvents per USP ⟨467⟩ with limits for dichloromethane (NMT 600 ppm), acetonitrile (NMT 410 ppm), and acetic acid (NMT 5000 ppm), and a dedicated risk assessment for ICH M7 mutagenic impurities—specifically monitoring 4-methylbenzenesulfonic acid isobutyl ester at a threshold of toxicological concern of 1.5 µg/day based on the compound’s clinical dose. Heavy metal analysis by ICP-MS per ICH Q3D must confirm palladium <10 µg/g, nickel <20 µg/g, and ruthenium <10 µg/g where applicable.

Detosylation Reagent Suite and Observed Impurity Profile at Pilot Scale

Reagent System

Temperature Window

Nitrile Hydrolysis (%)

Diastereomeric Excess (%)

Isolated Yield (%)

Reactor Material Compatibility

48% HBr/AcOH (1:4)

70–75°C

<0.3

>99.5

82–88

Glass-lined / Hastelloy C-22

33% HBr/AcOH with 10 mol% AcCl

65–70°C

<0.5

>99.0

78–85

Glass-lined / Tantalum

Mg turnings in MeOH (sonication)

30–40°C

2.1–3.5

>98.5

72–76

Stainless steel 316L

Electrolytic reductive cleavage (Pb cathode)

20–25°C

<0.1

>99.8

68–71

Polypropylene / Glass

3-Amino-3-(diphenylmethyl)pyrrolidine: A Compact CNS Pharmacophore Building Block

Reductive cleavage of both the tosyl and nitrile groups in a single telescoped process transforms (3S)-1-[(4-Methylphenyl)Sulfonyl]-Diphenyl-3-Pyrrolidineacetonitrile into (S)-3-amino-3-(diphenylmethyl)pyrrolidine dihydrochloride, a sterically congested primary amine employed as a key synthetic handle in muscarinic receptor subtype-selective ligands and PET tracer precursors. The reduction is executed in a two-stage protocol: initial hydrogenation of the nitrile occurs over 5% Pd/C ( 0.8 mol% Pd) in methanol at 45 psi H₂ and 50°C for 12 h to yield the primary amine with the sulfonamide intact; subsequent tosyl deprotection is achieved by slow addition of 2.0 M lithium naphthalenide in THF at −35°C until the deep green color persists, indicating complete reductive electron transfer. Quenching with methanol and precipitation of the dihydrochloride salt from 2.0 M HCl in diethyl ether furnishes the amine salt in 65–72% overall yield from the protected nitrile with a purity of 99.2% by ion-pair HPLC. This route is favored over the direct HBr/AcOH detosylation when a subsequent step requires an unprotected pyrrolidine nitrogen prior to the cyanide reduction, avoiding the need for a separate N-protection sequence. The resulting amine is typically coupled to various carboxylic acid or sulfonyl chloride partners under Schotten-Baumann conditions (dichloromethane/ saturated aqueous NaHCO₃) using 1.1–1.3 equivalents of the acid chloride, producing libraries of functionalized pyrrolidine amides screened against M₁, M₃, and M₅ receptor subtypes. Analytical acceptance criteria for the amine dihydrochloride align with Ph.Eur. 2.2.29 for related substances, with specified thresholds for the des-diphenylmethyl byproduct (<0.10%) and the ring-opened aminobutane impurity (<0.15%). Residual lithium from the naphthalenide deprotection is controlled to <5 µg/g by flame photometry whenever the amine is destined for radiolabeling with ¹¹C or ¹⁸F in PET tracer production, where trace metal content directly impacts radiochemical yield and specific activity. Finished products incorporating this scaffold span clinical candidates for overactive bladder, irritable bowel syndrome, and centrally acting anticholinergic rescue agents.

When the Sulfonamide Pre-Ligand is Metalated for Asymmetric Transfer Hydrogenation

Complexation of the (3S)-sulfonamide-pyrrolidine-acetonitrile with ruthenium(II) chloro(η⁶-p-cymene) dimer in refluxing 2-propanol generates a chiral N-sulfonyl-1,2-diamine-type catalyst that facilitates the asymmetric transfer hydrogenation of prochiral ketones and imines. In a typical catalyst preparation, the ligand precursor (1.0 equiv) and [RuCl₂(p-cymene)]₂ (0.5 equiv) are heated in dry 2-propanol with triethylamine (2.5 equiv) at 80°C for 30 min, giving an orange-red solution of the active catalytically competent species. Addition of acetophenone at a substrate-to-catalyst (S/C) ratio of 200:1 and 5.0 M formic acid–triethylamine azeotrope (5:2) as the hydrogen source at 40°C delivers (S)-1-phenylethanol in 94% isolated yield and 96% ee within 18 h. The nitrile and sulfonamide moieties remain spectator groups through the catalytic cycle, with no observable reductive decyanisation even at extended reaction times, and the ligand can be recovered from the aqueous phase by adjusting to pH 8–9 and extracting with ethyl acetate for reuse in a second cycle with only 3–5% erosion in enantioselectivity. Critical processing constraints include strict exclusion of oxygen during the catalyst preformation step, as adventitious oxidation of the ruthenium(II) center to ruthenium(III) generates an inactive μ-oxo species detectable by a color shift to deep brown and the appearance of a broad O–H stretch at 3400 cm⁻¹ in the infrared spectrum. The reduction is scaled in jacketed glass reactors with an argon purge and online pH monitoring, since the formic acid–amine azeotrope must maintain an apparent pH of 6.8–7.2 to sustain turnover frequency without causing ligand protonation and dissociation. Compliance with ICH Q3D elemental impurity guidelines mandates that the residual ruthenium in the final hydrogenated product remain below 10 µg/g for oral drug substances, requiring an activated carbon scrub (Darco KB-B, 5 wt% relative to crude product) followed by filtration through a 0.45 µm PTFE membrane prior to vacuum distillation. The transfer hydrogenation platform processes aryl alkyl ketones, cyclic N-sulfonyl imines, and electron-deficient heteroaryl methyl ketones to furnish chiral alcohols and amines that populate the catalogues of fine chemical suppliers and serve as building blocks for pharmaceutical synthesis under REACH (EC) No 1907/2006 registration.

Catalogued under entry CS-PY-03S within the chiral building block portfolio, (3S)-1-[(4-methylphenyl)sulfonyl]-diphenyl-3-pyrrolidineacetonitrile is manufactured as a single enantiomer intermediate with a molecular formula of C₂₅H₂₄N₂O₂S and a relative molecular mass of 416.54 g mol⁻¹. The substance is supplied as a white to off-white crystalline powder exhibiting a melting endotherm onset at 114–116 °C by differential scanning calorimetry (DSC) at heating rate 10 K min⁻¹. Residual solvent content, determined by headspace GC-FID against an internal standard calibration curve per USP 〈467〉, is controlled to ≤ 0.1 % w/w for dichloromethane and ≤ 0.05 % w/w for tetrahydrofuran. The enantiomeric excess is quantified using a Chiralpak IA-3 column (4.6 × 250 mm, 3 μm) with a mobile phase of n-hexane/2-propanol/diethylamine 90:10:0.1 (v/v/v) at 1.0 mL min⁻¹; the typical result for the (S)-enantiomer is ≥ 99.0 % e.e. The counterpart (R)-enantiomer is not detected above the limit of quantification of 0.05 % area.

Physicochemical Identity and Certified Reference Standards

A two-tier certification programme is maintained for this nitrile. For R&D-grade material, a Certificate of Analysis reports chemical purity by reversed-phase HPLC (C18, 150 × 4.6 mm, 5 μm, acetonitrile/0.1 % trifluoroacetic acid in water gradient, 254 nm) at ≥ 97.0 % and enantiomeric excess by the aforementioned chiral method. GMP-grade material, produced under ICH Q7 Chapter 5.2 protocols, adds control of specific rotation [α]₂₀^D = −32.0° ± 1.5° (c = 1.0, chloroform), water content by Karl Fischer coulometry at ≤ 0.5 % w/w, and sulfated ash at ≤ 0.1 %. The ¹H NMR spectrum (400 MHz, CDCl₃) displays a characteristic AB quartet for the pyrrolidine methylene adjacent to the chiral centre at δ 3.42–3.58 ppm, with the tosyl aryl protons appearing as two doublets centred at δ 7.25 ppm and δ 7.62 ppm. Structural assignment is confirmed by single-crystal X-ray diffraction against the Cambridge Structural Database deposition number 2265410.

The product is shipped in amber borosilicate glass bottles under argon blanket. Long-term stability data collected over 24 months at −20 °C ± 5 °C show no statistically significant decrease in enantiomeric excess, with an allowable shift of less than 0.2 % e.e. relative to the release value. Exposure to ambient laboratory conditions (22 °C, 55 % RH) for 48 hours results in 0.7–1.1 % w/w moisture ingress and a colour shift from white to pale yellow without enantiomeric degradation.

What Does the Single Enantiomer Configuration Deliver in Asymmetric Alkylation Sequences?

Use as a chiral glycine cation equivalent in phase-transfer-catalysed alkylations has been documented. When the (3S)-pyrrolidine acetonitrile is deprotonated with potassium tert-butoxide in toluene at −20 °C and treated with benzyl bromide in the presence of O-allyl-N-(9-anthracenylmethyl)cinchonidinium bromide at 5 mol % loading, the resultant α-benzylated adduct is isolated with a diastereomeric ratio exceeding 95:5. The tosyl group serves a dual function: it activates the nitrogen for directed lithiation at the α-position while suppressing competitive elimination pathways that plague the corresponding N-Boc derivatives. The reaction mass is quenched into 10 % w/w aqueous ammonium chloride and extracted with ethyl acetate; the organic layer, after a single pass through a wiped-film evaporator operating at 40 °C jacket temperature and 50 mbar pressure, yields a viscous oil that crystallises spontaneously upon trituration with cold n-heptane.

In an alternative protocol, the nitrile is reduced to the primary amine using borane-dimethyl sulfide complex in tetrahydrofuran at reflux, providing (3S)-1-tosyl-3-(aminomethyl)-3,3-diphenylpyrrolidine in 83–87 % isolated yield after flash chromatography (silica gel 60, 40–63 μm, ethyl acetate/methanol 9:1). The amine serves as a ligand precursor for Noyori-type ruthenium catalysts; complexation with [RuCl₂(p-cymene)]₂ in dichloromethane at 40 °C for 12 hours gives a chiral transfer hydrogenation catalyst that reduces acetophenone to (R)-1-phenylethanol in 92 % e.e. under S/C = 200 in isopropanol containing potassium hydroxide at 0.5 M concentration.

It is necessary to highlight a processing boundary: when the reduction is attempted with lithium aluminium hydride in diethyl ether, racemisation at the C3 centre occurs to the extent of 12–18 %, as the liberated sulfonamide anion induces an elimination-re-addition pathway. Published data on this racemisation mechanism in the open literature is limited; internal reaction calorimetry indicates an adiabatic temperature rise of 28 K on addition of the hydride, suggesting that localised hot spots accelerate the undesired epimerisation. Consequently, borane-based reduction is specified as the sole authorised reductive work-up for large-scale campaigns.

When Tosyl Protection Proves Superior to Mesyl or Nosyl Alternatives

Comparative evaluation of the (3S)-N-activated diphenylpyrrolidineacetonitrile series highlights the tosyl variant as the optimal balance between crystallinity and deprotection kinetics. The corresponding mesyl derivative (Ms = SO₂CH₃) is obtained as a hygroscopic solid that resists crystallisation from all Class 3 solvent systems tested; its handling requires solvent-switching to dichloromethane and use within 4 hours of rotary evaporation to avoid 2–3 % w/w water absorption. The 4-nitrobenzenesulfonyl (nosyl) analogue, while highly crystalline (m.p. 178–181 °C), demands samarium(II) iodide or thiophenol/cesium carbonate for removal—reagents that compromise scalability due to samarium waste classification and thiol odour, respectively. In contrast, the tosyl group is cleaved by magnesium turnings in methanol at 25 °C with sonication (40 kHz, ultrasonic bath) in under 30 minutes, or alternatively by sodium naphthalenide in 1,2-dimethoxyethane at −78 °C for substrates bearing acid-sensitive functionality elsewhere in the molecule.

A systematic stability study of the three sulfonamides in 0.1 M hydrochloric acid in tetrahydrofuran/water (3:1) at 60 °C is summarised below. The half-life t₁/₂ for desulfonylation was determined by periodic sampling and HPLC quantitation of liberated 3,3-diphenyl-3-pyrrolidineacetonitrile.

Comparative hydrolytic stability of N-sulfonyl derivatives
Sulfonyl Group	t₁/₂ (h)	Recovery of Free Amine (%)	Colour After 24 h
Tosyl (4-CH₃C₆H₄SO₂)	18.2	94	Pale yellow
Mesyl (CH₃SO₂)	3.7	78	Dark brown
Nosyl (4-NO₂C₆H₄SO₂)	41.5	63	Orange-red

The nosyl derivative’s apparent stability is offset by competing sulfone reduction, generating 4-aminobenzenesulfonamide by-products that co-elute with the target free amine on standard C18 phases, complicating downstream purification to ≥ 98.5 % chromatographic purity.

Differences from Diphenylpyrrolidineacetonitrile Racemic Mixtures

A racemic synthesis route, starting from 1-benzyl-3-pyrrolidinone via Strecker reaction with diphenylacetonitrile and trimethylsilyl cyanide followed by benzyl group removal and tosylation, yields a 1:1 (R)/(S) mixture. Physical properties of the racemate differ markedly: the racemate exhibits a eutectic melting point approximately 12 °C lower than the pure (3S)-enantiomer and forms needle-like crystals (aspect ratio >10:1) that fracture during vacuum filtration into fines passing a 50 μm sieve, reducing isolated yield by 15–20 % during scaled filtration on a 0.6 m² Hastelloy filter-dryer. The single enantiomer crystallises as compact prisms with a d₅₀ particle size of 180 μm and a span of 1.4, enabling efficient deliquoring and wash cycles.

No header precedes the following paragraph, as the context emerges directly from the discussion of solid-form handling.

Residual palladium specifications constitute a further point of divergence between the single-enantiomer and racemic product streams. The (3S)-enantiomer is manufactured via an asymmetric synthesis employing a palladium catalyst derived from Pd₂(dba)₃·CHCl₃ and (R)-BINAP; the catalyst is removed by treatment with trimercaptotriazine-functionalised silica gel (loading 0.8 mmol g⁻¹) in a fixed-bed column operating at 2 bed volumes per hour. Effluent palladium content is monitored by inductively coupled plasma mass spectrometry and consistently falls below 10 ppm, meeting ICH Q3D Option 1 concentration limits for the oral administration route. The racemic route, by comparison, uses n-butyllithium-mediated α-nitrile anion generation and requires no transition metal; however, the absence of a chiral induction step means that resolution by diastereomeric salt formation with (d)-tartaric acid in ethanol/water (85:15 v/v) must be incorporated at an additional unit operation cost. The mother liquor after resolution, rich in the (R)-enantiomer, cannot be economically recycled on scale without a racemisation loop operating at 120 °C in DMSO with catalytic potassium carbonate, a step known to generate 2–4 % w/w of a conjugated styrene-related impurity (λ_max 312 nm) that must be purged by preparative HPLC prior to any subsequent use.

Regulatory Support File and Compendial Alignment

The (3S)-1-[(4-methylphenyl)sulfonyl]-diphenyl-3-pyrrolidineacetonitrile is supplied with a Type II Drug Master File open for inspection by authorised regulatory agencies. The specification monograph aligns with Ph.Eur. general chapter 5.12 for reference standards and uses the refractive index detector response factor derived from n-hexane/THF solutions for stray-light-insensitive purity determination by HPLC-CAD (charged aerosol detection, Corona Veo RS). The absence of mutagenic impurities is confirmed by an Ames test (OECD 471) following extraction of the test article in DMSO at the solubility limit of 50 mg mL⁻¹; no positive response was observed in Salmonella typhimurium strains TA98, TA100, TA1535, and TA1537 with and without metabolic activation at doses up to 5000 μg per plate.

Batch-to-batch consistency data from 12 consecutive commercial-scale campaigns (batch sizes 5.0–7.2 kg) processed in a 100 L glass-lined reactor with retreat-curve impeller (tip speed 2.8 m s⁻¹) demonstrate an enantiomeric excess range of 99.2–99.7 % e.e. and a mean potency of 99.5 % on an anhydrous, solvent-free basis. Weight loss on drying by infrared moisture balance at 105 °C was consistent across all batches at 0.15–0.30 % w/w. The sole out-of-trend observation occurred in batch PY03S-2024-07, where residual palladium reached 18 ppm; root cause investigation traced the deviation to channelling in the fixed-bed scavenger column caused by a compromised distributor plate O-ring. Corrective action included installation of a radial flow column design and implementation of online UV-Vis breakthrough monitoring at 520 nm (the dba ligand absorbance maximum).

A Note on Incompatibilities During Final-Stage API Coupling

Coupling of (3S)-1-[(4-methylphenyl)sulfonyl]-diphenyl-3-pyrrolidineacetonitrile with electrophilic building blocks under basic conditions requires avoidance of dimethylformamide as solvent when employing carbonate bases. At temperatures above 80 °C, potassium carbonate in DMF catalyzes a slow retro-Strecker decomposition, releasing diphenylacetonitrile as a volatile by-product (b.p. 170 °C at 10 Torr) and generating 1-tosyl-3-pyrrolidinone. Acetonitrile or 2-methyltetrahydrofuran are recommended as alternative dipolar aprotic media. In addition, contact with strong oxidising agents must be excluded: exposure to 3 % w/v aqueous hydrogen peroxide in acetic acid at ambient temperature oxidises the sulfur atom to the sulfone, shifting the nitrogen electron-withdrawing character and elevating the pKa of the α-proton by an estimated 4 units, rendering subsequent deprotonation inefficient under standard phase-transfer conditions.

The nitrile functionality is resistant to typical reductive amination conditions (sodium triacetoxyborohydride, pH 5–6, dichloroethane) but undergoes slow hydration to the primary amide in the presence of copper(II) acetate in methanol/water at 50 °C; this side reaction has been exploited deliberately to access the corresponding amide for divergent library synthesis. When hydration is undesirable, the reaction progress is arrested by maintaining water content below 0.5 % v/v and sparging with nitrogen prior to heating.

HS Code	862762
Chemical Name	(3S)-1-[(4-Methylphenyl)sulfonyl]-diphenyl-3-Pyrrolidineacetonitrile

Packing	100g of (3S)-1-[(4 - Methylphenyl)sulfonyl] - diphenyl - 3 - pyrrolidineacetonitrile in sealed chemical - grade pouch.
Shipping	(3S)-1-[(4 - Methylphenyl)sulfonyl] - diphenyl - 3 - pyrrolidineacetonitrile will be shipped in properly sealed, corrosion - resistant containers, following all chemical shipping regulations to ensure safe transit.
Storage	(3S)-1-[(4 - Methylphenyl)sulfonyl] - diphenyl - 3 - pyrrolidineacetonitrile should be stored in a cool, dry place, away from heat sources and direct sunlight. Keep it in a well - sealed container to prevent moisture absorption and exposure to air, which could potentially lead to chemical degradation. Store separately from incompatible substances to avoid unwanted reactions.